NCT01075945

Brief Summary

Dihydroartemisinin- Piperaquine is not inferior to artemether-lumefantrine

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
140

participants targeted

Target at P50-P75 for phase_4

Timeline
Completed

Started Feb 2010

Shorter than P25 for phase_4

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 1, 2010

Completed
17 days until next milestone

First Submitted

Initial submission to the registry

February 18, 2010

Completed
7 days until next milestone

First Posted

Study publicly available on registry

February 25, 2010

Completed
1 month until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2010

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2010

Completed
Last Updated

February 25, 2010

Status Verified

February 1, 2010

Enrollment Period

2 months

First QC Date

February 18, 2010

Last Update Submit

February 24, 2010

Conditions

Keywords

antimalarialsACTsPiperaquineuncomplicated

Outcome Measures

Primary Outcomes (1)

  • comparing the cure rate between the two drugs

    PCR cure rate Parasite clearance time Fever clearance time

    3 months

Study Arms (2)

Dihydroartemisinin- piperaquine

EXPERIMENTAL

orally tablets

Drug: Dihydroartemisinin- piperaquineDrug: artemether- lumefantrine

artemether- lumefantrine

ACTIVE COMPARATOR

oral tablets

Drug: artemether- lumefantrine

Interventions

three tablets per day

Also known as: Hoy-Cotec
Dihydroartemisinin- piperaquine

twenty tablet in eight doses

Also known as: Coartem
Dihydroartemisinin- piperaquineartemether- lumefantrine

Eligibility Criteria

Age5 Years - 95 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • Uncomplicated malaria

You may not qualify if:

  • Severe cases
  • Pregnancy

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Sinnar

Cinnar, Blue Nile, 11111, Sudan

RECRUITING

Related Publications (1)

  • Adam I, Elmardi KA, Malik EM. Predictors of antimalarial treatment failure in an area of unstable malaria transmission in eastern Sudan. Trans R Soc Trop Med Hyg. 2009 Jan;103(1):21-4. doi: 10.1016/j.trstmh.2008.07.005. Epub 2008 Aug 20.

    PMID: 18718621BACKGROUND

MeSH Terms

Conditions

Malaria

Interventions

Artemether, Lumefantrine Drug Combination

Condition Hierarchy (Ancestors)

Protozoan InfectionsParasitic DiseasesInfectionsMosquito-Borne DiseasesVector Borne Diseases

Intervention Hierarchy (Ancestors)

ArtemetherArtemisininsReactive Oxygen SpeciesFree RadicalsInorganic ChemicalsOrganic ChemicalsLumefantrineFluorenesPolycyclic Aromatic HydrocarbonsHydrocarbons, AromaticHydrocarbons, CyclicHydrocarbonsSesquiterpenesTerpenesPolycyclic CompoundsDrug CombinationsPharmaceutical Preparations

Central Study Contacts

Ishag Adam, MD, PhD

CONTACT

Fatih M Malik, MD

CONTACT

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER

Study Record Dates

First Submitted

February 18, 2010

First Posted

February 25, 2010

Study Start

February 1, 2010

Primary Completion

April 1, 2010

Study Completion

April 1, 2010

Last Updated

February 25, 2010

Record last verified: 2010-02

Locations